Eric Price

Eric Price is a researcher specializing in radiopharmaceutical chemistry, focusing on the development of novel chelators for radiometals such as zirconium-89, gallium-68, copper-64, and lutetium-177. His work bridges inorganic chemistry, organic synthesis, and molecular imaging to create targeted agents for cancer and bacterial infection diagnostics and therapies.

• BSc Honours, Co-op (2009), University of Victoria
• PhD (2014), University of British Columbia, supervised by Dr. Chris Orvig

Dr. Price's research emphasizes improving radiolabeling stability and tissue distribution through innovative ligand design. His lab develops acyclic chelators like H₄octapa and H₂azapa, which enable precise radiometal coordination for imaging (PET/SPECT) and therapeutic applications. Key areas include cancer targeting, antibiotic-resistant infections, and radioimmunoconjugates.

Recent publications highlight advancements in Silicon-Fluoride Acceptor (SiFA) methodology, zwitterionic peptide modifications, and cleavable linker systems. His work has been featured in journals like Journal of the American Chemical Society and Dalton Transactions, with an invited contribution to the Barry Lever Special Issue in Canadian Journal of Chemistry.

• Invited manuscript for ACS Langmuir special issue on Supramolecular Chemistry at Interfaces
• Co-inventor on EP Patent 2,536,691 for bifunctional chelating agents